Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are related inflammatory disorders that often coexist. Both are most common among women, whites, and older individuals. PMR is characterized by morning stiffness, pain, and decreased range of motion in the shoulders, neck, and pelvis. Diagnosing PMR can be challenging because no standard set of criteria or single diagnostic test exists. Patients with PMR benefit rapidly from treatment with oral glucocorticoids, and full recovery is likely, although adverse effects of treatment contribute to morbidity. GCA is a subacute vasculitis in which focal, segmental inflammatory infiltrates primarily affect cranial arteries. Diagnosis of GCA is based on clinical features, such as headache, jaw pain, vision changes, and temporal artery tenderness, along with an elevated erythrocyte sedimentation rate and inflammation seen on temporal artery biopsy. Permanent vision loss can occur, so patients who may have temporal arteritis should be started on glucocorticoids promptly. If treatment for GCA is started before visual symptoms progress, the prognosis for a full recovery is good. In PMR and GCA, relapses or exacerbations necessitating changes in therapy occur in up to 60% of patients.

Download full-text PDF

Source

Publication Analysis

Top Keywords

polymyalgia rheumatica
8
giant cell
8
cell arteritis
8
full recovery
8
temporal artery
8
pmr
5
gca
5
myalgias myopathies
4
myopathies polymyalgia
4
rheumatica giant
4

Similar Publications

Shoulder Injury Related to Vaccine Administration (SIRVA) is a complication caused by improperly administered vaccinations. It triggers an inflammatory cascade that damages shoulder structures, resulting in prolonged shoulder pain and restricted range of motion. Common diagnoses in SIRVA patients include shoulder bursitis (all classified as subacromial bursitis), adhesive capsulitis, and rotator cuff injuries such as tears or tendinopathy.

View Article and Find Full Text PDF

Objectives: This study aimed to describe the characteristics, inflammatory markers as surrogates for disease activity, and treatment of patients with polymyalgia rheumatica (PMR) in Japan.

Methods: This cohort study analysed the data of 373 patients with PMR retrieved from an electronic medical records database in Japan. Patients were classified into quartiles, based on the daily glucocorticoid dose over the initial 90 days of treatment (Q1-Q4).

View Article and Find Full Text PDF

A glucocorticoid-free era for polymyalgia rheumatica: are we on the brink of change?

Lancet Rheumatol

January 2025

Department of Rheumatology, Hospital of Brunico, Teaching Hospital of the Paracelsius Medical University, Brunico 39031, Italy; Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Medical University, Graz, Austria. Electronic address:

View Article and Find Full Text PDF

Background: Moderate doses of glucocorticoids result in improvements in nearly all patients with polymyalgia rheumatica, but related adverse events are common in older individuals. We aimed to evaluate whether treatment with baricitinib (a Janus kinase 1/2 inhibitor) results in disease control without the use of oral glucocorticoids in people with recent-onset polymyalgia rheumatica.

Methods: We conducted a randomised, double-blind, placebo-controlled, parallel-group trial at six expert centres in France.

View Article and Find Full Text PDF

Background: Diagnosis of Giant Cell Arteritis (GCA) and Polymyalgia rheumatica (PMR) may be challenging as many patients present with non-specific symptoms. Superficial cranial arteries are predilection sites of inflammatory affection. Ultrasound is typically the diagnostic tool of first choice supplementary to clinical and laboratory examination.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!